Saturday - December 21, 2024
AstraZeneca: Datopotamab Deruxtecan Granted Breakthrough Therapy Designation in U.S. for Patients With Previously Treated Advanced EGFR-Mutated Non-Small Cell Lung Cancer
December 10, 2024
WILMINGTON, Delaware, Dec. 10 (TNSres) -- AstraZeneca, a biopharmaceutical company, issued the following news release:

* * *

First Breakthrough Therapy Designation for AstraZeneca and Daiichi Sankyo's datopotamab deruxtecan

Based on TROPION-Lung05 Phase II trial and supported by data from TROPION-Lung01 Phase III trial

* * *

Datopotamab deruxtecan (Dato-DXd) has been granted Breakthrough Therapy Designation (BTD) in the US for the . . .

Targeted News Service Document Request Form

This document is available to you by e-mail if you complete the form below with relevant information. There may be a fee for this article or ongoing service of similar materials. We will be in touch shortly.

Name:
What's your
Affiliation		 Government Newspaper / Media Business
Public Policy Individual / Student Educators
Email:
Phone:
Organization, if any:
State/Country you are in:
Additonal questions
or comments:

Click here for more information about our products

Click here for more information about our products